Liminatus Pharma Announces Board and Officer Changes

Ticker: LIMNW · Form: 8-K · Filed: Jul 11, 2025 · CIK: 1971387

Liminatus Pharma, Inc. 8-K Filing Summary
FieldDetail
CompanyLiminatus Pharma, Inc. (LIMNW)
Form Type8-K
Filed DateJul 11, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: corporate-governance, management-change

TL;DR

Liminatus Pharma (LMPX) reshuffled its board and officers on 7/10/25.

AI Summary

Liminatus Pharma, Inc. announced on July 10, 2025, changes in its board of directors and officer appointments. The company, formerly known as Iris Parent Holding Corp. until March 28, 2023, is incorporated in Delaware and operates in the biological products sector.

Why It Matters

Changes in a company's leadership and board can signal shifts in strategy or governance, impacting investor confidence and future performance.

Risk Assessment

Risk Level: low — This filing reports routine corporate governance changes and does not involve significant financial transactions or operational shifts.

Key Players & Entities

  • Liminatus Pharma, Inc. (company) — Registrant
  • Iris Parent Holding Corp. (company) — Former company name
  • 20250710 (date) — Date of earliest event reported
  • 20250711 (date) — Filing date
  • Delaware (jurisdiction) — State of incorporation

FAQ

What specific changes were made to the board of directors and officer positions?

The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' but does not detail the specific individuals or roles affected in the provided text.

When was Liminatus Pharma, Inc. previously known as Iris Parent Holding Corp.?

The company's name was changed from Iris Parent Holding Corp. on March 28, 2023.

What is the primary business of Liminatus Pharma, Inc.?

Liminatus Pharma, Inc. is in the business of Biological Products (No Diagnostic Substances), with a Standard Industrial Classification code of 2836.

Where is Liminatus Pharma, Inc. headquartered?

The company's business and mailing address is 6 Centerpointe Drive, #625, La Palma, CA 90623.

What is the SEC file number for Liminatus Pharma, Inc.?

The SEC file number for Liminatus Pharma, Inc. is 001-42626.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on July 11, 2025 regarding Liminatus Pharma, Inc. (LIMNW).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.